Nuvation Bio Inc. (NUVB) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $4.28: Risk below floor (3.0 < 3.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10 and A.R:R 10.7:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 24%; Below-average business quality; Negative price momentum.
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It... Read more
Sell if holding. Engine safety override at $4.28: Risk below floor (3.0 < 3.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10 and A.R:R 10.7:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 24%; Below-average business quality; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 5.0/10, moderate confidence.
Passes 6/7 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, earnings proximity 80d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: aggressive.
Recent Developments — Nuvation Bio Inc.
Latest news
- Nuvation Bio Collaborates With Thermo Fisher Scientific For U.S.-Based Manufacturing Of IBTROZI — benzinga May 13, 2026 positive
- RBC Capital Reiterates Outperform on Nuvation Bio, Maintains $20 Price Target — benzinga May 5, 2026 positive
- Wedbush Reiterates Outperform on Nuvation Bio, Maintains $11 Price Target — benzinga May 5, 2026 positive
- HC Wainwright & Co. Reiterates Buy on Nuvation Bio, Maintains $17 Price Target — benzinga May 5, 2026 positive
- Nuvation Bio Q1 EPS $0.01, Inline, Sales $83.228M Beat $62.259M Estimate. — benzinga May 4, 2026 positive
Generated 2026-05-20T21:06:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
1 floor-breaker
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $4.28: Risk below floor (3.0 < 3.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10 and A.R:R 10.7:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 24%; Below-average business quality; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $4.00. Score 5.0/10, moderate confidence.
Take-profit target: $10.73 (+154.9% upside). Prior stop was $4.00. Stop-loss: $4.00.
Risk below floor (3.0 < 3.0).
Nuvation Bio Inc. trades at a P/E of N/A (forward -72.0). TrendMatrix value score: 6.6/10. Verdict: Sell.
17 analysts cover NUVB with a consensus score of 4.1/5. Average price target: $12.
What does Nuvation Bio Inc. do?Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer...
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma with safusidenib against placebo. The company was founded in 2018 and is headquartered in New York, New York.